GLP-1 receptor agonists are generating buzz for their metabolic benefits, as well as for their potential to directly combat breast cancer progression.
News|Articles|January 28, 2026
- Vol.27/No.3
- Volume 27
Ultrasensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan, Ron Panarotti
The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.
Advertisement
Advertisement
Ultrasensitive circulating tumor DNA (ctDNA) monitoring is increasingly reframing how metastatic breast cancer clinical trials are designed and how treatment decisions may be timed, shifting the focus from reacting to radiographic progression to intervening at the earliest molecular signs of resistance.1
Related to this article
T-DXd plus pertuzumab was approved in the European Union as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.
Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.
A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.
Brain cancer experts explain the current wave of surgical advances and advocate for team-based, multidisciplinary strategies to individualize patient care.
Advertisement
Advertisement